ArticleHeart (British Cardiac Society)2026
Sex differences in the prevalence and prognosis of tricuspid regurgitation among patients with heart failure.
Article in Heart (British Cardiac Society), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04570098 (Prevalence and Prognostic Relevance of Tricuspid Regurgitation in Different Heart Failure Entities), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence and Prognostic Relevance of Tricuspid Regurgitation in Different Heart Failure Entities
Who cites it
2 citing papers in PubMed.
- Prevalence of Tricuspid Regurgitation and Mortality Outcomes in Patients With Heart Failure: Stratification by Phenotype.JACC. Advances · 2026Article
- Beyond the left ventricle: modern echocardiographic assessment of right ventricular function in tricuspid regurgitation.Cardiovascular ultrasound · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTricuspid regurgitation (TR) is a common finding in heart failure (HF) and is associated with adverse outcomes. Data about sex differences in TR prevalence, aetiology and prognosis among patients with HF and their subgroups are still scarce.
methodsPatients with HF with a recent transthoracic echocardiography were enrolled in our registry (NCT04570098). Based on a left ventricular ejection fraction (LVEF) cut-off of 50%, patients were divided into those with reduced (rEF) and preserved ejection fraction (pEF). Follow-ups were conducted after 3, 6 and 12 months. Analysis was performed in the overall cohort and after matching for age and comorbidities.
resultsBetween 2020 and 2022, 1012 patients with HF were prospectively enrolled, including 38% women. pEF was more prevalent among females (60%), whereas rEF was more common among males (60%) (p<0.001). Women presented a higher prevalence of at least moderate TR (42%) compared with men (29%) without significant differences regarding TR aetiology. Severe TR was associated with increased mortality in women with pEF (HR 2.341, 95% CI 1.075 to 5.098, p=0.032) and men with rEF (HR 3.163, 95% CI 1.675 to 5.973, p<0.001), while there was only a non-significant trend in the opposite cohorts. These findings were consistent even after matching. Moreover, severe TR was associated with hospitalisations in both HF cohorts and with cardiovascular hospitalisation in male patients, but not female patients with HF.
conclusionA higher TR prevalence was observed in women compared with men without differences in TR aetiology. Severe TR may predict mortality in female patients with pEF and male patients with rEF, but not vice versa. These results may have an impact on sex-specific follow-up and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.